Home Biosimilar Antibodies Immunology & Inflammation CD markers Anti-TNFRSF4 / OX40 / CD134 (BMS-986178)
For research use only. Not for use in humans.

Anti-TNFRSF4 / OX40 / CD134 (BMS-986178)

Synonyms: INCAGN01949

Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) is a fully human immunoglobulin monoclonal antibody targeting OX40. It is used in treatment of in patients with advanced solid tumors. MW :150 KD.

Anti-TNFRSF4 / OX40 / CD134 (BMS-986178)

Quality Control

Batch: A308301 Purity: 99% Protein concentration: 4.93mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-TNFRSF4 / OX40 / CD134 (BMS-986178) is a fully human immunoglobulin monoclonal antibody targeting OX40. It is used in treatment of in patients with advanced solid tumors. MW :150 KD.
References

Product Details

Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03410901 COMPLETED Drug: TLR9 Agonist SD-101 B-Cell Non-Hodgkin Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Lymphoplasmacytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma Ronald Levy 2018-04-09 PHASE1
NCT03831295 COMPLETED Drug: TLR9 Agonist SD-101 Advanced Malignant Solid Neoplasm; Extracranial Solid Neoplasm; Metastatic Malignant Solid Neoplasm Ronald Levy 2019-03-13 PHASE1
NCT02737475 COMPLETED Drug: BMS-986178|Drug: Nivolumab|Drug: Ipilimumab|Drug: Cycl Advanced Cancer Bristol-Myers Squibb 2016-06-17 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2024-12-11)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.